BCRX - BioCryst Pharmaceuticals, Inc.
NEXT EARNINGS:
Feb 26, 2026
(in 1 day)
EPS Est: $0.07
|
Rev Est: $151.3M
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$14.40
DETAILS
HIGH:
$25.00
LOW:
$8.00
MEDIAN:
$15.00
CONSENSUS:
$14.40
UPSIDE:
89.22%
Market Cap:
1.60B
Volume:
1,860,893
Avg Volume:
4,177,620
52 Week Range:
6-11.31
Sector:
Healthcare
Industry:
Biotechnology
Beta:
0.79
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
580
IPO Date:
1994-03-04
EPS (TTM):
-0.43
P/E Ratio:
-17.49
Revenue (TTM):
450.71M
Total Assets:
490.42M
Total Debt:
841.42M
Cash & Equiv:
104.92M
Rev Growth (5Y):
55.9%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
3.5%
Debt/Equity:
-1.77
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-11-03 | $0.06 | $0.07 | -14.3% | $159.4M | $151.3M | +5.3% |
| 2025-08-04 | $0.15 | $0.03 | +400.0% | $163.4M | $149.6M | +9.2% |
| 2025-05-05 | $0.00 | $-0.07 | +100.2% | $145.5M | $149.7M | -2.8% |
| 2025-02-24 | $-0.13 | $-0.07 | -85.7% | $131.5M | $126.6M | +3.9% |
| 2024-11-04 | $-0.07 | $-0.07 | 0.0% | $117.1M | $127.7M | -8.3% |
| 2024-08-05 | $-0.06 | $-0.19 | +68.4% | $109.3M | $98.3M | +11.2% |
| 2024-05-06 | $-0.17 | $-0.23 | +26.1% | $92.8M | $85.6M | +8.4% |
| 2024-02-26 | $-0.28 | $-0.24 | -16.7% | $93.4M | $90.0M | +3.8% |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 450.71M | 331.41M | 270.83M | 157.17M | 17.81M | 48.84M | 20.65M | 25.19M | 26.35M | 48.26M | 13.61M | 17.33M |
| Net Income | (88.88M) | (226.54M) | (247.12M) | (184.06M) | (182.81M) | (108.90M) | (101.25M) | (65.78M) | (55.14M) | (43.02M) | (45.19M) | (30.11M) |
| EPS | -0.43 | -1.18 | -1.33 | -1.03 | -1.09 | -0.94 | -0.98 | -0.78 | -0.75 | -0.59 | -0.68 | -0.55 |
| Total Assets | 490.42M | 516.96M | 550.00M | 588.15M | 334.71M | 175.28M | 146.84M | 178.26M | 89.85M | 124.56M | 136.87M | 48.87M |
| Total Debt | 841.42M | 825.15M | 741.45M | 593.24M | 279.50M | 84.65M | 61.82M | 54.72M | 53.72M | 32.38M | 30.00M | 30.00M |
| Cash & Equivalents | 104.92M | 110.64M | 304.77M | 504.39M | 272.13M | 114.17M | 26.73M | 50.28M | 22.10M | 28.90M | 54.54M | 21.16M |
| Operating Cash Flow | (52.02M) | (95.14M) | (161.85M) | (142.16M) | (137.22M) | (89.58M) | (92.56M) | (41.14M) | (53.44M) | (13.12M) | (38.55M) | (26.53M) |
| Free Cash Flow | (53.14M) | (97.31M) | (163.20M) | (144.54M) | (137.73M) | (89.93M) | (92.93M) | (41.47M) | (58.72M) | (18.24M) | (38.66M) | (26.56M) |
| FCF per Share | -0.26 | -0.51 | -0.88 | -0.81 | -0.82 | -0.78 | -0.90 | -0.49 | -0.80 | -0.25 | -0.58 | -0.48 |
| Book Value | (475.93M) | (455.53M) | (294.60M) | (106.99M) | (19.26M) | 38.25M | (731.97M) | (631.84M) | (566.06M) | (510.92M) | (467.90M) | (422.71M) |
| Cash & ST Investments | 321.06M | 388.99M | 424.31M | 507.60M | 300.37M | 136.23M | 126.84M | 155.69M | 63.58M | 99.25M | 113.89M | 40.64M |
| ROC Equity | N/A | N/A | N/A | N/A | N/A | -2.85 | N/A | N/A | N/A | N/A | N/A | N/A |